FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation.

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer FDA medical oncologists discuss the agency’s December 2016 accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies.

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

The D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Transcript

FDA D.I.S.C.O.: First Tissue/Site Agnostic Approval Transcript

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

FDA D.I.S.C.O.: L-glutamine for sickle cell disease. FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease.

FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.

FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia FDA medical oncologists discuss the Aug. 3, 2017, approval of Vyxeos for treatment of acute myelogenous leukemia.

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer

FDA medical oncologists discuss the first approval of a chimeric antigen receptor (CAR) T-cell immunotherapy.

FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy

FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma.

FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

FDA D.I.S.C.O.: A new drug approval for non-metastatic castration-resistant prostate cancer

hubhopper

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C...

hubhopper